Enzymatically stable analogue of the gut-derived peptide xenin on beta-cell transdifferentiation in high fat fed and insulin-deficient Ins1Cre/+;Rosa26-eYFP mice
- 1 March 2021
- journal article
- research article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 37 (3), e3384
- https://doi.org/10.1002/dmrr.3384
Abstract
Background: The antidiabetic effects of the gut hormone xenin include augmenting insulin secretion and positively affecting pancreatic islet architecture. Methods: The current study has further probed pancreatic effects through sub-chronic administration of the long-acting xenin analogue, xenin-25[Lys(13)PAL], in both high fat fed (HFF) and streptozotocin (STZ)-induced insulin-deficientIns1(Cre/+);Rosa26-eYFPtransgenic mice. Parallel effects on metabolic control and pancreatic islet morphology, including islet beta-cell lineage tracing were also assessed. Results: Xenin-25[Lys(13)PAL] treatment reversed body weight loss induced by STZ, increased plasma insulin and decreased blood glucose levels. There were less obvious effects on these parameters in HFF mice, but all xenin-25[Lys(13)PAL] treated mice exhibited decreased pancreatic alpha-cell areas and circulating glucagon. Xenin-25[Lys(13)PAL] treatment fully, or partially, returned overall islet and beta-cell areas in STZ- and HFF mice to those of lean control animals, respectively, and was consistently associated with decreased beta-cell apoptosis. Interestingly, xenin-25[Lys(13)PAL] also increased beta-cell proliferation and decreased alpha-cell apoptosis in STZ mice, with reduced alpha-cell growth noted in HFF mice. Lineage tracing studies revealed that xenin-25[Lys(13)PAL] reduced the number of insulin positive pancreatic islet cells that lost their beta-cell identity, in keeping with a decreased transition of insulin positive to glucagon positive cells. These beneficial effects on islet cell differentiation were linked to maintained expression of Pdx1 within beta-cells. Xenin-25[Lys(13)PAL] treatment was also associated with increased numbers of smaller sized islets in both models. Conclusions: Benefits of xenin-25[Lys(13)PAL] on diabetes includes positive modulation of islet cell differentiation, in addition to promoting beta-cell growth and survival.Funding Information
- Invest Northern Ireland
- European Foundation for the Study of Diabetes
- Diabetes UK
This publication has 60 references indexed in Scilit:
- Inactivation of specific β cell transcription factors in type 2 diabetesJCI Insight, 2013
- Beta-Cell Dedifferentiation and Type 2 DiabetesThe New England Journal of Medicine, 2013
- Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25Biochemical Pharmacology, 2012
- In Vitro Proliferation of Adult Human Beta-CellsPLOS ONE, 2012
- Context-specific α-to-β-cell reprogramming by forced Pdx1 expressionGenes & Development, 2011
- Xenin-25 Potentiates Glucose-dependent Insulinotropic Polypeptide Action via a Novel Cholinergic Relay MechanismOnline Journal of Public Health Informatics, 2010
- Conversion of adult pancreatic α-cells to β-cells after extreme β-cell lossNature, 2010
- The Ectopic Expression of Pax4 in the Mouse Pancreas Converts Progenitor Cells into α and Subsequently β CellsCell, 2009
- Interleukin-6 regulates pancreatic α-cell mass expansionProceedings of the National Academy of Sciences of the United States of America, 2008
- Embryonic endocrine pancreas and mature β cells acquire α and PP cell phenotypes upon Arx misexpressionJCI Insight, 2007